Younes Fegheh-Hassanpour, R&D tax manager at financial advisor RCK Partners explains how the UK can spark global competitiveness in the life sciences industry

Jay Shah ponders whether CDMO deals will revive next year to define pharma M&A.

Marion Jeng, associate at investment bank DAI Magister, identifies the femtech sectors healthcare investors should prioritise.